Links
- ORCID
- Crossref | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
Journal article published in 2013 by
Gerasimos Filippatos,
John R. Teerlink,
Dimitrios Farmakis,
Gad Cotter,
Beth A. Davison,
G. Michael Felker,
G. Michael Felker,
Barry H. Greenberg,
Tsushung Hua,
Piotr Ponikowski,
Thomas Severin,
Elaine Unemori,
Adriaan A. Voors,
Marco Metra 
Abstract
Aims Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-AHF trial. Methods and results RELAX-AHF randomized 1161 AHF patients to 48-h serelaxin (30 mu g/kg/day) or placebo within 16 h from presentation. We compared the effects of serelaxin on efficacy endpoints, safety endpoints, and biomarkers of organ damage between preserved (a parts per thousand yen50%) and reduced (